[Autom. eng. transl.] As part of an HTA process, it is analyzed - from an ethical point of view - the use of megalgy in the treatment of actinic keratosis, bearing in mind the implications related to respect for the autonomy of the subject, to the risk / benefit ratio and the problems related to its entry into the SSN.
|Translated title of the contribution||[Autom. eng. transl.] Ethical analysis in an Ingenol mebutate HTA process|
|Number of pages||3|
|Journal||Italian Journal of Public Health|
|Publication status||Published - 2013|
- health technology assessment